Cardiology 2013 (Full reference info)

Reference Type: Journal Article
Record Number: 784Author: Hausenloy, D. J., Erik Botker, H., Condorelli, G., Ferdinandy, P., Garcia-Dorado, D., Heusch, G., Lecour, S., van Laake, L. W., Madonna, R., Ruiz-Meana, M., Schulz, R., Sluijter, J. P., Yellon, D. M. and Ovize, M.
Year: 2013
Title: Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology
Journal: Cardiovasc Res
Volume: 98
Issue: 1
Pages: 7-27
Date: Apr 1
Short Title: Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology
Alternate Journal: Cardiovascular research
ISSN: 1755-3245 (Electronic)
0008-6363 (Linking)
DOI: 10.1093/cvr/cvt004
Accession Number: 23334258
Keywords: Animals
Cardiopulmonary Bypass
Cardiopulmonary Resuscitation
Collateral Circulation
Coronary Artery Bypass
Coronary Circulation
Coronary Disease/complications/*therapy
Disease Models, Animal
Heart Transplantation
Humans
Myocardial Reperfusion Injury/*prevention & control
Signal Transduction
Abstract: Coronary heart disease (CHD) is the leading cause of death and disability worldwide. Despite current therapy, the morbidity and mortality for patients with CHD remains significant. The most important manifestations of CHD arise from acute myocardial ischaemia-reperfusion injury (IRI) in terms of cardiomyocyte death and its long-term consequences. As such, new therapeutic interventions are required to protect the heart against the detrimental effects of acute IRI and improve clinical outcomes. Although a large number of cardioprotective therapies discovered in pre-clinical studies have been investigated in CHD patients, few have been translated into the clinical setting, and a significant number of these have failed to show any benefit in terms of reduced myocardial infarction and improved clinical outcomes. Because of this, there is currently no effective therapy for protecting the heart against the detrimental effects of acute IRI in patients with CHD. One major factor for this lack of success in translating cardioprotective therapies into the clinical setting can be attributed to problems with the clinical study design. Many of these clinical studies have not taken into consideration the important data provided from previously published pre-clinical and clinical studies. The overall aim of this ESC Working Group Cellular Biology of the Heart Position Paper is to provide recommendations for optimizing the design of clinical cardioprotection studies, which should hopefully result in new and effective therapeutic interventions for the future benefit of CHD patients.
Notes: Hausenloy, Derek J
Erik Botker, Hans
Condorelli, Gianluigi
Ferdinandy, Peter
Garcia-Dorado, David
Heusch, Gerd
Lecour, Sandrine
van Laake, Linda W
Madonna, Rosalinda
Ruiz-Meana, Marisol
Schulz, Rainer
Sluijter, Joost P G
Yellon, Derek M
Ovize, Michel
eng
FS/06/023/British Heart Foundation/United Kingdom
Department of Health/United Kingdom
Research Support, Non-U.S. Gov’t
Review
England
2013/01/22 06:00
Cardiovasc Res. 2013 Apr 1;98(1):7-27. doi: 10.1093/cvr/cvt004. Epub 2013 Jan 19.
URL: http://www.ncbi.nlm.nih.gov/pubmed/23334258
Author Address: The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London WC1E 6HX, UK. d.hausenloy@ucl.ac.uk

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155